Trials / Completed
CompletedNCT00134251
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations. Patients (outpatients) will be randomized to one of three different treatment arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLV308 |
Timeline
- Start date
- 2005-10-01
- First posted
- 2005-08-24
- Last updated
- 2009-01-30
Locations
10 sites across 3 countries: Bulgaria, Malta, Serbia
Source: ClinicalTrials.gov record NCT00134251. Inclusion in this directory is not an endorsement.